Home LiteratureArticle Details
PMID: 11553815 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL

Abstract

The purpose of this study was to classify breast carcinomas based on variations in gene expression patterns derived from cDNA microarrays and to correlate tumor characteristics to clinical outcome. A total of 85 cDNA microarray experiments representing 78 cancers, three fibroadenomas, and four normal breast tissues were analyzed by hierarchical clustering. As reported previously, the cancers could be classified into a basal epithelial-like group, an ERBB2-overexpressing group and a normal breast-like group based on variations in gene expression. A novel finding was that the previously characterized luminal epithelial/estrogen receptor-positive group could be divided into at least two subgroups, each with a distinctive expression profile. These subtypes proved to be reasonably robust by clustering using two different gene sets: first, a set of 456 cDNA clones previously selected to reflect intrinsic properties of the tumors and, second, a gene set that highly correlated with patient outcome. Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.

MeSH Terms
Algorithms Breast Neoplasms/classification,genetics Carcinoma in Situ/classification,genetics Carcinoma, Ductal, Breast/classification,genetics Carcinoma, Lobular/classification,genetics DNA, Neoplasm Female Fibroadenoma/classification,genetics Gene Expression Gene Expression Profiling Humans Oligonucleotide Array Sequence Analysis/methods Tumor Suppressor Protein p53/genetics
Chemicals
DNA, Neoplasm Tumor Suppressor Protein p53
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Sørlie T
Department of Genetics, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway.
Perou C M
Tibshirani R
Aas T
Geisler S
Johnsen H
Hastie T
Eisen M B
van de Rijn M
Jeffrey S S
Thorsen T
Quist H
Matese J C
Brown P O
Botstein D
Lønning P E
Børresen-Dale A L
References (20)
20 references, click to expand
  1. Gene-expression profiles in hereditary breast cancer.
    N Engl J Med. 2001 Feb 22;344(8):539-48 PMID: 11207349
  2. Molecular portraits of human breast tumours.
    Nature. 2000 Aug 17;406(6797):747-52 PMID: 10963602
  3. Significance analysis of microarrays applied to the ionizing radiation response.
    Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 PMID: 11309499
  4. The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease.
    Br J Cancer. 1983 May;47(5):629-40 PMID: 6849801
  5. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients.
    Cancer. 1986 Mar 15;57(6):1171-80 PMID: 3943040
  6. Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement.
    Eur J Cancer Clin Oncol. 1988 Nov;24(11):1685-90 PMID: 3061825
  7. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
    Science. 1989 May 12;244(4905):707-12 PMID: 2470152
  8. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
    Histopathology. 1991 Nov;19(5):403-10 PMID: 1757079
  9. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators.
    Cancer. 1993 Mar 15;71(6 Suppl):2141-50 PMID: 8443763
  10. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy.
    Nat Med. 1995 Oct;1(10):1029-34 PMID: 7489358
  11. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains.
    Genes Chromosomes Cancer. 1995 Sep;14(1):71-5 PMID: 8527388
  12. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
    Nat Med. 1996 Jul;2(7):811-4 PMID: 8673929
  13. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
    J Pathol. 1996 May;179(1):31-8 PMID: 8691341
  14. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.
    Clin Chim Acta. 1997 Jun 27;262(1-2):99-119 PMID: 9204213
  15. Cluster analysis and display of genome-wide expression patterns.
    Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 PMID: 9843981
  16. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
    Br J Cancer. 1999 Jan;79(2):300-7 PMID: 9888472
  17. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
    Science. 1999 Oct 15;286(5439):531-7 PMID: 10521349
  18. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
    Nature. 2000 Feb 3;403(6769):503-11 PMID: 10676951
  19. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Cancer Res. 2000 Apr 15;60(8):2155-62 PMID: 10786679
  20. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Cancer Res. 2001 Mar 15;61(6):2505-12 PMID: 11289122
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
2001-09-11
Pages
10869-74
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC58566
Subset
IM
Grants
NCI NIH HHS · U01 CA085129 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com